Serán Featured Guest in Biospace Denatured Podcast: The Unintended Consequences of Small Molecules

Continuing on from the previous episode of Biospace's Denatured "The Gap is Where the Pain Is", this episode focuses on a healthy discussion regarding the IRA, particularly the unintended consequences of small molecule development within the industry and for patients.

Serán CEO Dan Smithey, alongside industry thought leaders, focus in on small molecule development, considerations and potential reasoning behind negotiated patent timelines for small vs. large molecules, and next steps toward a solution to equalize the negotiation timeline.

‍

Host

⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace  

Guests

⁠⁠Ali Pashazadeh⁠⁠, CEO, Treehill Partners

⁠⁠Dan Smithey⁠⁠, President, CEO and Co-founder, Serán BioScience

⁠⁠Matthew Price⁠⁠, COO and Co-founder, Promontory Therapeutics

⁠⁠Peter Rubin⁠⁠, Executive Director, No Patient Left Behind

⁠⁠Rob Williamson⁠⁠, President and COO, Triumvira Immunologics

‍

Listen on Spotify. Approximately 25-minute listening time.